Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Lenvatinib/Everolimus in Advanced Kidney Cancer: Outcomes in a Real-World Setting

By: Cordi Craig, MS
Posted: Friday, July 16, 2021

Interest is growing in real-world data, outside of clinical trials, among patients, providers, the U.S. Food and Drug Administration, and other stakeholders to develop and expand new drugs and indications. However, few real-world studies have examined the efficacy of the kinase inhibitors lenvatinib and everolimus among patients with advanced or metastatic renal cell carcinoma. A longitudinal, retrospective study, published in Clinical Genitourinary Cancer, reported that the combination therapy may be effective among a heavily pretreated patient population in real-world settings.

“This is the first study to show that clinical outcomes of patients receiving lenvatinib and everolimus in the community oncology setting are comparable to those of patients in clinical trials,” Nizar M. Tannir, MD, FACP, of MD Anderson Cancer Center, Houston, and colleagues claimed.

Using data from the US Oncology Network, the study team retrospectively examined 79 adults with advanced or metastatic renal cell carcinoma who began treatment with lenvatinib and everolimus between May 13, 2016, and July 31, 2019. The researchers assessed patients’ characteristics, treatment patterns, and outcomes.

Patients were treated with immuno-oncology–based regimens (39.2%) or tyrosine kinase inhibitors (50.6%) directly before initiating lenvatinib and everolimus treatment. The median overall survival was 14.8 months, and the median progression-free survival was 6.1 months. For patients treated with immuno-oncology and tyrosine kinase inhibitors, the median progression-free survival was 6.4 months and 5.7 months, respectively. Although just 1.6% of patients achieved complete responses, more than half of the patient population (54.1%) achieved some degree of tumor size reduction. The median time to treatment discontinuation was 5.7 months, and the median duration of response was 9.7 months.

“Future research can expand on these findings to explore patient characteristics related to lenvatinib and everolimus outcomes in clinical practice,” the study team concluded.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.